haniel.araujo (@_hanielaraujo) 's Twitter Profile
haniel.araujo

@_hanielaraujo

Assistant Professor - Thoracic Medical Oncology - MD Anderson Cancer Center

ID: 1266720396000276480

calendar_today30-05-2020 13:17:39

12 Tweet

105 Followers

84 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
Elizabeth McKenna (@elizsmckenna) 's Twitter Profile Photo
Elizabeth McKenna
@elizsmckenna

a year ago

@HCCvPDAC Lastly, haniel.araujo, Ximo Pechuan-Jorge, PhD, Teng Zhou, Ferdinandos Skoulidis, et al show in NSCLC the RAS(ON) multiselective inhibitor RMC-7977 is active in KRASG12C-mut models resistant to G12C inhibitors, but a mucinous txtn state supports drug tolerance doi.org/10.1158/2159-8… MD Anderson Cancer Center

@HCCvPDAC Lastly, <a href="/_hanielaraujo/">haniel.araujo</a>, <a href="/XimoPechuan/">Ximo Pechuan-Jorge, PhD</a>, Teng Zhou, <a href="/FSkoulidis/">Ferdinandos Skoulidis</a>, et al show in NSCLC the RAS(ON) multiselective inhibitor RMC-7977 is active in KRASG12C-mut models resistant to G12C inhibitors, but a mucinous txtn state supports drug tolerance doi.org/10.1158/2159-8… <a href="/MDAndersonNews/">MD Anderson Cancer Center</a>
Ferdinandos Skoulidis (@fskoulidis) 's Twitter Profile Photo
Ferdinandos Skoulidis
@fskoulidis

10 months ago

Excited to share our new study nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow haniel.araujo and Minh Truong Do. Thankful to our patients. MD Anderson Cancer Center

Excited to share our new study <a href="/Nature/">nature</a>. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow <a href="/_hanielaraujo/">haniel.araujo</a> and <a href="/minhtruongdo/">Minh Truong Do</a>. Thankful to our patients. <a href="/MDAndersonNews/">MD Anderson Cancer Center</a>
DAVA Oncology (@davaonc) 's Twitter Profile Photo
DAVA Oncology
@davaonc

a month ago

Dr. Haniel Araujo(haniel.araujo )MD Anderson Cancer Center outlined phase 1 results for zoldonrasib, an oral covalent RAS(ON)-G12D inhibitor: ORR 61 % in KRAS G12D NSCLC at the 1200 mg QD RP2D; median time-to-response 1.4 mo and mostly grade 1 AEs. RMC-LUNG-101 expansion is now enrolling.

Dr. Haniel Araujo(<a href="/_hanielaraujo/">haniel.araujo</a> )<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> outlined phase 1 results for zoldonrasib, an oral covalent RAS(ON)-G12D inhibitor: ORR 61 % in KRAS G12D NSCLC at the 1200 mg QD RP2D; median time-to-response 1.4 mo and mostly grade 1 AEs. RMC-LUNG-101 expansion is now enrolling.